Alzheimer's Disease

A global harmonized proteomics dataset of Alzheimer’s, Parkinson’s, and FTD uncovers disease signatures to accelerate diagnostics and therapeutic discovery

Researchers report that dried blood spots can reliably measure p-tau217 and other Alzheimer’s biomarkers in a controlled research setting

The findings provide fresh insights into the potential health risks posed by environmental plastics

At the ADLM 2025, Roche highlights advances in diagnostics, including digital health solutions, mass spectrometry, and expanded access to testing across care settings

The new “iPSC Platform to Model Alzheimer’s disease Risk” (IPMAR) resource will be made available to researchers worldwide

First blood-based in vitro diagnostic test to receive FDA clearance to help identify patients with amyloid pathology associated with Alzheimer’s disease

New test provides less invasive option, reduces reliance on PET scans, and increases diagnosis accessibility

In a proof-of-concept study, the test detected five key biomarkers of Alzheimer’s disease—more than current commercially available blood tests can measure

VeraBIND™ Tau is a new noninvasive test that offers 96 percent sensitivity and 90 percent specificity, empowering earlier and more accessible Alzheimer's detection

Better diagnostics for neurodegenerative diseases can improve clinical trials to help move groundbreaking therapies to approval